Fate Therapeutics (NASDAQ:FATE – Get Free Report) released its earnings results on Monday. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.12, MarketWatch Earnings reports. Fate Therapeutics had a negative return on equity of 36.63% and a negative net margin of 253.30%. The firm […]

Related Keywords

Canada , Bahram Valamehr , Voya Investment Management , Nuveen Asset Management , Barclays Plc , Wells Fargo Company , Redmile Group Llc , Fate Therapeutics Inc , Royal Bank , Fate Therapeutics Company Profile , Fate Therapeutics , Get Free Report , Marketwatch Earnings , Director Redmile Group , Investment Management , Asset Management , Howard Capital Management , Fate Therapeutics Daily ,